Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnostic value of Gd-EOB-DTPA-enhanced MRI radiomics models for dual-phenotype hepatocellular carcinoma].

Zhonghua yi xue za zhi·2024
Same author

Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Extending the spectral database of laser-induced breakdown spectroscopy with generative adversarial nets.

Optics express·2019
Same author

Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir.

Acta virologica·2013
Same author

Kinetics of retroviral production from the amphotropic ΨCRIP murine producer cell line.

Cytotechnology·2012
Same author

Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling.

Diabetologia·2011

Related Experiment Video

Updated: Feb 2, 2026

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
07:54

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy

Published on: December 15, 2011

13.5K

[Research progress of ischemic hepatitis].

B Q Shen1, L Q Dong, Y Ma

  • 1Department of Hepatic Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|November 28, 2018
PubMed
Summary
This summary is machine-generated.

Ischemic hepatitis, or shock liver, causes liver cell damage due to insufficient blood flow. Treatment focuses on correcting hemodynamic issues, as this condition has a high mortality rate.

Keywords:
HepatitisIschemiaLiver failureShock

More Related Videos

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

279
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

Related Experiment Videos

Last Updated: Feb 2, 2026

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
07:54

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy

Published on: December 15, 2011

13.5K
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

279
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

Area of Science:

  • Hepatology
  • Critical Care Medicine

Background:

  • Ischemic hepatitis (hypoxic hepatitis or shock liver) is liver cell damage without other causes of acute hepatitis.
  • Characterized by transaminase levels >20x normal, it affects 2.5-10% of patients and has >50% hospital mortality.
  • Risk factors include hypotension, low cardiac output, sepsis, and respiratory distress, all leading to hepatocyte dysfunction.

Purpose of the Study:

  • To review current research on the etiology, mechanisms, and clinical manifestations of ischemic hepatitis.
  • To highlight the significance of hemodynamic disorders in the pathogenesis and treatment of this condition.

Main Methods:

  • Literature review of existing research on ischemic hepatitis.
  • Analysis of etiological factors, pathomechanisms, and clinical presentations.
  • Focus on the role of systemic hypotension and hemodynamic instability.

Main Results:

  • Ischemic hepatitis results from various conditions causing inadequate oxygen supply to the liver.
  • Hepatocyte dysfunction is the ultimate manifestation, driven by underlying hemodynamic disorders.
  • Systemic hypotension is a critical factor associated with high mortality.

Conclusions:

  • Effective treatment of ischemic hepatitis hinges on the prompt correction of hemodynamic derangements.
  • Understanding the etiology and mechanisms is crucial for improving patient outcomes in this high-mortality condition.